Check Out Our Recent Posts
New Study Data on Chemo-Immunotherapy Approach Using the ELIAS Cancer Immunotherapy (ECI®) to Treat Bone Cancer in Dogs Demonstrates Improved Outcomes
LENEXA, Kan., June 19, 2025 – ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced interim results from an ongoing clinical study [...]
The Body’s Inner Army: How Immunotherapy Trains the Immune System to Battle Cancer
Cancer immunotherapies are treatments that help a patient’s own immune system find and destroy cancer cells. Normally, the immune system might not recognize cancer cells [...]
Philip J. Bergman, DVM, PhD, DACVIM (Oncology) Joins ELIAS Animal Health Scientific Advisory Board
LENEXA, Kan., April 10, 2025 -- ELIAS Animal Health, a leading innovator in cancer immunotherapies for veterinary medicine, today announced that Dr. Philip J. Bergman, [...]
More Than a Cancer Vaccine
The ELIAS Cancer Immunotherapy (ECI®) if the first and only USDA-approved product for the treatment of canine osteosarcoma. ECI® is unique because of its dual approach to treatment: it brings together the power of a personalized cancer vaccination and activated “killer” T cell therapy to trigger the patient’s own immune system to attack cancer cells. Our immunotherapy enables veterinary care providers like you to:
Extend hope for families of pets with cancer
Make a measurable difference for your patients
Help improve outcomes with minimal adverse side effects